We were delighted to meet with Gregory Branigan (University of Arizona, AZ, USA) to discuss the impact of estrogen therapies on Alzheimer’s disease pathways.
The abstract entitled: ‘Breast Cancer Therapies Reduce Risk of Alzheimer’s Disease and Dementia: Clinic to Bench Translation’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
- What is the rationale for investigating the impact of estrogen modulating therapy (EMT) exposure on the risk of neurodegenerative disease (NDD) in women with breast cancer? (0:19)
- Could you tell us a little about your short study and its findings? (1:46)
- What is known about the molecular mechanisms underlying this observed risk reduction? (2:36)
- What are the wider implications of these findings? (4:06)
- What future studies are planned? (5:08)
Disclosures: Gregory Branigan has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
Share this Video
Related Videos In Alzheimer's Disease & Dementia
Ivana Rosenzweig, Sleep and Breathing 2021: The Link Between Sleep Apnoea and Dementia
We were delighted to speak with Dr Ivana Rosenzweig (Sleep and Brain Plasticity Centre, King’s College London, London, UK) around her talk on the ‘Link between sleep apnoea and dementia: the neuroimaging perspective‘, which was presented at the virtual 2021 Sleep and Breathing Conference, 16-17 April, 2021. Questions What is known about the relationship between […]
Jeffrey Cummings, AAN 2021: BAN2401 Effects On Brain Amyloid And ARIA-E Findings
touchNEUROLOGY caught up with Jeffrey Cummings (University of Nevada, Las Vegas, NV, USA) one of our Editorial Board Members, to discuss BAN2401’s use in early stage Alzheimer’s Disease, and Amyloid Related Imaging Abnormalities (ARIA)-E alterations and their utility in amyloid-modifying trials. The abstract entitled: ‘Preliminary Analysis Of BAN2401 Effects On Brain Amyloid And ARIA-E Findings […]
Jeffrey Cummings, AAN 2021: Phase 2b Study of BAN2401 in subjects with Early Alzheimer’s Disease
touchNEUROLOGY caught up with Jeffrey Cummings (University of Nevada, Las Vegas, NV, USA) one of our valued Editorial Board Members, to discuss the open-label extension of the Phase 2b Study (BAN2401-G000-201) in subjects with early Alzheimer’s Disease. The abstract entitled: ‘Preliminary Analysis Of BAN2401 Effects On Brain Amyloid And ARIA-E Findings Over 12 Months Of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!